Anúncios
relacionados a: colorectal cancer and brain metastasis pdfFrequent Questions For Physicians About Colorectal Cancer. HER2+ mCRC Treatment Option. Learn About An FDA-Approved Treatment Option For HER2+ Metastatic Colorectal Cancer.
- HER2+ mCRC Testing
Learn How To Test
Learn When to Test
- Clinical Study
Trial Design and Endpoints
Inlcusion Criteria Here
- Dosing & Administration
View Dosing Charts
Study Dosing Information Here
- Efficacy & Safety
Adverse Reactions Of Interest
Common Reactions Table
- HER2+ mCRC Testing
Leading to Faster Responses, Better Outcomes, Fewer Side Effects & More Hope. Designing the Best Treatment Plan & Therapies to Target Your Specific Cancer.
Learn More About Brain Tumor Treatment Options. Get Access to Our Free Treatment Guide. Cleveland Clinic's Brain Tumor Program Has Experts to Treat Your Condition. Call Now.
Read About the Benefits & Risks Of A Treatment Option, Access Patient Resources & Support. A Treatment Option For HER2+ Metastatic Breast Cancer. Downloads FAQs.
Resultado da Busca
21 de fev. de 2021 · Colorectal cancer (CRC) is the third most common malignancy worldwide. Most patients with metastatic CRC develop liver or lung metastases, while a minority suffer from brain metastases. There is little information available regarding the presentation, treatment, and overall survival of brain metastases (BM) from CRC.
21 de fev. de 2021 · Colorectal cancer (CRC) is the third most common malignancy worldwide. Most patients with metastatic CRC develop liver or lung metastases, while a minority suffer from brain metastases....
22 de jan. de 2021 · Conclusions: Brain metastases are rare in colorectal cancer but portend poor survival. Lung and bone metastases are found more frequently in these patients. Treatment with metastasectomy or multiagent chemotherapy is associated with improved overall survival.
- Suleyman Yasin Goksu, Muhammad Shaalan Beg, Aravind Sanjeevaiah, Emrah Gumusgoz, David Hsieh, Muhamm...
- 2021
204. Background: More than 50% of colorectal cancer (CRC) patients will develop metastatic disease. Brain metastasis (BM) from colorectal cancer is uncommon (0.6-1.36%). This study aims to investigate the patient characteristics, treatment modalities and prognostic factors in this rare population.
- Zhaohui Jin, William Breen, Rui Jin, Paul D. Brown, Joleen Marie Hubbard
- 2020
Brain metastases (BM) from colorectal cancer (CRC) are a rare event. However, the implications for affected patients are severe, and the incidence has been reported to be increasing. For clinicians, knowledge about the characteristics associated with BM is important and could lead to earlier diagnosis and improved survival. Method:
Our study supports the low incidence of brain metastasis in patients with colorectal cancer. A unique set of characteristics is identified to confer an increased risk of brain metastases. Keywords Brain metastasis · Predictors · Colorectal cancer · Incidence. Introduction.
